Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681724 | 0.83 | TRPV4 (0.39) | TRPV4CCR2LMNAHSD17B10EPAS1 | |
| SCHEMBL27138022 | 0.83 | TRPV4 (0.39) | TRPV4CCR2LMNAHSD17B10EPAS1 | |
| SCHEMBL4131352 | 0.83 | LMNA (0.33) | CCR2LMNAHSD17B10 | |
| SCHEMBL32690962 | 0.82 | TRPV4 (0.42) | TRPV4CCR2LMNAEPAS1 | |
| SCHEMBL9450298 | 0.81 | LMNA (0.32) | CCR2LMNAHSD17B10 | |
| SCHEMBL29668868 | 0.80 | HSD17B10 (0.40) | TRPV4CCR2LMNAHSD17B10 | |
| SCHEMBL533092 | 0.80 | HSD17B10 (0.40) | TRPV4CCR2LMNAHSD17B10 | |
| SCHEMBL31160887 | 0.80 | TRPV4 (0.33) | TRPV4EPAS1 | |
| SCHEMBL10014826 | 0.79 | TET2 (0.39) | LMNAHSD17B10 | |
| SCHEMBL20485940 | 0.79 | TET2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466934-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2974730-B1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO CO LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-9597330-B2 | Drugs for treating respiratory diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2974730-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| EP-1940785-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SmithKline Beecham Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885CCR2 492/4885LMNA 3671/4885 |
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | SCN1B, NHERF1, SCNN1A | TRPV4 454/4885CCR2 797/4885LMNA 869/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | TRPV4 23/4885CCR2 727/4885LMNA 2474/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | TRPV4 23/4885CCR2 727/4885LMNA 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.